Drug Shortage Report for SODIUM ACETATE INJECTION, USP
| Report ID | 193516 |
| Drug Identification Number | 02139529 |
| Brand name | SODIUM ACETATE INJECTION, USP |
| Common or Proper name | SODIUM ACETATE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | SODIUM ACETATE |
| Strength(s) | 328MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 50 mL |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-08-01 |
| Actual start date | |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2023-08-02 |
| Company comments | Fresenius Kabi Canada would like to advise that our Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL will be removed off allocation effective June 1, 2023. This product will be available to all customers without restrictions. Our inventory is expected to be depleted by August 1, 2023, after which, the long-term supply status is still unknown. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2023-08-02 | English | Compare |
| v2 | 2023-06-01 | French | Compare |
| v1 | 2023-06-01 | English | Compare |
Showing 1 to 3 of 3